Hu Shih-Wen, Chuang Je-Hen, Tsai Kun-Bow
Department of Pathology, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan.
Kaohsiung J Med Sci. 2006 May;22(5):235-42. doi: 10.1016/S1607-551X(09)70242-6.
Male breast cancer is rare, and the incidence is less than 1% of all breast malignancies in both men and women. It is possible that, because male patients are unaware of male breast cancer, there is a delay of diagnosis and, consequently, more advanced stages are commonly encountered in these patients. Some studies have engaged in molecular studies of male breast cancers because of the possibly different characteristics, prognosis, and treatment between male and female malignancies. However, a dearth of studies still exists, most likely because of the rarity of the disease and lack of a large patient base for study. Among the molecular markers of breast cancer, p53, Ki-67, HER-2/neu, and Bcl-2 are the most frequently studied. Here we present two rare cases and a review of the literature concerning the relationship between immunohistochemical markers and their impact in order to provide surgeons with more information about the disease and further techniques for treatment of these patients.
男性乳腺癌较为罕见，其发病率在所有男性和女性乳腺恶性肿瘤中不足1%。由于男性患者对男性乳腺癌缺乏认知，可能会导致诊断延误，因此这些患者中通常会遇到更晚期的病例。由于男性和女性恶性肿瘤在特征、预后和治疗方面可能存在差异，一些研究已致力于男性乳腺癌的分子研究。然而，研究仍然匮乏，这很可能是由于该疾病的罕见性以及缺乏用于研究的大量患者群体。在乳腺癌的分子标志物中，p53、Ki-67、HER-2/neu和Bcl-2是研究最为频繁的。在此，我们呈现两例罕见病例并对有关免疫组化标志物之间的关系及其影响的文献进行综述，以便为外科医生提供更多关于该疾病的信息以及治疗这些患者的进一步技术。
